Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 7, 2025
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 --
Read more at globenewswire.com
